ACE and diabetic kidney disease: Finerenone has been shown to reduce the UACR in patients with DKD treated with a renin-angiotensin system (RAS) blocker (i.e., ACE inhibitors or ARBs) while having smaller effects on serum potassium levels than other MRAs [61].